Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bellerophon Therapeutics names COO

This article was originally published in Scrip

Executive Summary

Bellerophon Therapeutics, a clinical-stage biotherapeutics company, has appointed Amit Agrawal chief operating officer, effective 8 July, and Dr Naseem Amin an independent director of the company, effective 29 June. Mr Agrawal joins Bellerophon from Amgen, where, since 2012, he was director of strategy and corporate development. While at Amgen, Mr Agrawal worked across several areas of the business covering R&D, manufacturing operations, commercial planning and business development. Meanwhile, Dr Amin, who was also appointed to Bellerophon's audit committee, has broad industry experience in the biotech and medical device industries. Until 2014, he was chief scientific officer of Smith and Nephew, where he provided scientific leadership to the organization. 


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts